Creative Biogene offers testing services for detection of rcAAV in compliance with FDA, ICH, and CPMP guidelines. We have established a method to detect rcAAV more sensitively and rapidly. With years of experience in biosafety assessment, we can design a customized testing program to assess the potency, purity, and safety of your viral vaccine or gene therapy product at phase-appropriate levels (R&D, GLP, and GMP) to support your regulatory filing.